



Commercial PA Criteria
Effective: November 9, 2023

Prior Authorization: Miebo (perfluorohexyloctane)

Products Affected: Miebo (perfluorohexyloctane) ophthalmic solution

Medication Description: MIEBO (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED). Perfluorohexyloctane, a semifluorinated alkane, contains 6 perfluorinated carbon atoms and 8 hydrogenated carbon atoms. Perfluorohexyloctane forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation. The exact mechanism of action in dry eye disease is not known.

Covered Uses:

1. Treatment of the signs and symptoms of dry eye disease (DED)

Exclusion Criteria:

1. Patient is not concomitantly using with an ophthalmic cyclosporine product (Cequa, Restasis, Vevye), Tyrvaya (varenicline nasal solution), or Xiidra (lifitegrast ophthalmic solution)

Required Medical Information:

1. Diagnosis
2. Past therapies tried and failed

Prescriber Restriction: The medication is prescribed by, or in consultation with, an ophthalmologist or optometrist

Age Restriction: 18 years and older

Coverage Duration: 12 months

Other Criteria:

Initial Approval Criteria

1. Dry Eye Disease

- A. Patient is ≥ 18 years of age; **AND**
- B. Patient is not concomitantly using with an ophthalmic cyclosporine product (Cequa, Restasis, Vevye), Tyrvaya (varenicline nasal solution), or Xiidra (lifitegrast ophthalmic solution); **AND**
- C. Patient has tried and failed artificial tears; **AND**
- D. Patient has had an adequate trial with Cyclosporine Ophthalmic solution (generic Restasis) **AND** Xiidra; **AND**
- E. The medication is prescribed by or in consultation with an ophthalmologist or optometrist

November 2023



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.



References:

1. Product Information: MIEBO™ ophthalmic solution, perfluorohexyloctane ophthalmic solution. Bausch & Lomb Americas Inc (per FDA), Bridgewater, NJ, 2023.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	11/09/2023

November 2023



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.